Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET

Completed

Conditions: Differentiated tyroid carcinoma
thyroid cancer
10043739
10014713

Registration Number: NL-OMON38034

Lead Sponsor: Antoni van Leeuwenhoek Ziekenhuis

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 100

Inclusion Criteria

1. Patients with a history of differentiated thyroid cancer
2. After complete thyroidectomy and ablation of functional remnants with 131I.
3. Planned for blind high dose 131I treatment based on biochemically suspected recurrence, defined as a Tg-level above 2.0 ng/ml.
4. Ultrasonography of the neck performed < 2 months prior to inclusion.

Exclusion Criteria

1. Age < 18 years
2. Pregnancy
3. Incapacitated subjects
4. Contrast enhanced CT performed < 4 months prior to inclusion
5. I-131 therapy performed < 12 months prior to inclusion
6. Indication for other therapy modality (ie. surgery in case of a positive ultrasonography, radiotherapy, embolization or chemotherapy)

Study & Design

Study Type: Observational invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>- The number of futile 131I treatments that can be avoided using this imaging<br /><br>strategy.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Synchronised introduction and QA/QC of 124I-PET in the Netherlands<br /><br>- Translational correlation of 124I-PET and FDG-PET with histopathology (where<br /><br>available) and treatment outcome, in an explorative setting.<br /><br>- To investigate whether 124I-PET has the same diagnostic, dosimetric and<br /><br>prognostic yield during stimulation with rhTSH and hormone withdrawal combined<br /><br>with low-idodine diet.</p><br>